Summary: NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.

Takeaways:

  1. NeoGenomics’ solid tumor and lung cancer assays, based on next-generation sequencing, provide a more comprehensive and cost-effective diagnostic solution compared to single-gene tests.
  2. New York State’s conditional approval confirms NeoGenomics’ adherence to stringent testing standards, allowing the company to expand access to its tests for healthcare providers and patients in the state.
  3. The NeoTYPE DNA & RNA Lung assay fills a critical gap in lung cancer testing by detecting a broad range of genetic markers that may be missed by single-gene tests, aligning with national cancer treatment guidelines.

NeoGenomics, an oncology testing services company, announced that the New York State Department of Health (NYSDOH) has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE DNA & RNA Lung, allowing for immediate commercial access in the state of New York. 

These next-generation sequencing (NGS) tests deliver better diagnostic value and cost-effectiveness than single gene testing and direct the first-line treatment of diverse solid tumors, including non-small cell lung cancer.

Approval of the Solid Tumor Test

New York State is known for having stringent validation standards for laboratory-developed tests. Clinical laboratories testing specimens from New York residents must obtain a clinical laboratory permit from NYSDOH to help ensure the accuracy and reliability of clinical tests.

“Receiving approval for Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung from NYSDOH marks a significant milestone for NeoGenomics, confirming the company’s high standards for developing new tests, the quality of our lab results, and the impact these tests have on guiding management of diverse cancers,” says Warren Stone, CCO of NeoGenomics. “More importantly, NeoGenomics can now bring these tests to more healthcare providers and their patients across New York state, continuing our mission of transforming care for cancer patients.”

Further reading: NeoGenomics Launches New Sequencing Assay for Rapid Genetic Profiling of AML

Supporting Lung Cancer Diagnosis

Each year, 116,000 people are diagnosed with cancer in New York State, with lung cancer representing the leading cause of cancer-related death. Neo Comprehensive offers physicians a pan-cancer genomic profiling solution that aligns with National Comprehensive Cancer Network (NCCN) guidelines for diverse cancers. NeoTYPE DNA & RNA Lung leverages the same technology as Neo Comprehensive Solid Tumor but in the context of a more focused NGS panel that addresses an unmet need in lung cancer testing across the state. These tests analyze a broad panel of genes, which detect less common genetic markers that cancer-specific profiles or single-gene tests may miss.

NeoGenomics operates Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited laboratories for full-sample processing across the U.S. Widely recognized as the highest standard for clinical laboratory accreditations, the CAP Laboratory Accreditation Program is designed to ensure laboratories meet stringent requirements and standards of quality, safety, and accuracy.